BioWorld

March 21, 2008

View Archived Issues

Presidio Gains Early Hepatitis C Program from XTL in $108M Deal

Small antiviral firm Presidio Pharmaceuticals Inc. picked up rights to a group of preclinical small molecules targeting hepatitis C virus in a potential $108 million deal with XTL Biopharmaceuticals Ltd. (BioWorld Today) Read More

Cephalon Gets Much-Anticipated Nod for Treanda in CLL Patients

Read More

New Herpes Co-Receptor Found in Research Study

Read More

EPIX Cancels Depression Drug Following Phase IIb Failure

Read More

PharmAthene Buys Vaccines from Avecia in $40M Deal

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More